B-amyloid peptides
- 제품용도
- peptide를 이용한 다양한 실험에 활용 가능
- 브랜드
- ANASPEC
- 개요
- Amyloid plaque의 주요 구성 요소 인 Beta-Amyloid (1-42)는 알츠하이머 병 뇌의 neuron에 축적됩니다. AnaSpec은 또한 방대한 β-Amyloid peptide 컬렉션을 제공합니다.
HOME >
제품특징
High Quality
- 고순도의 펩타이드 제공 (Purity: ≥95% by HPLC)
- ISO 9001 certified
- 경험과 지식이 풍부한 전문 인력에 의해 제조
- Peptide의 counter-ion: TFA (trifluoroacetic acid)
- Industry standard 중량
AggreSureTM Beta-Amyloid 1-42 & 1-40 Peptides
- Guaranteed for aggregation
SensoLyte® ThT Aβ42 or Aβ40 Aggregation kits를 사용하여 aggregation을 확인
Fluorescence signal is correlated with an increase of Aß42 fibril formation. Phenol Red, Morin, Tannic Acid, Dopamine, and o-Vanillin were added at 100µM final concentration to inhibit Aß42
Fluorescence signal is correlated with an increase of Aß40 fibril formation. Phenol Red, Morin, Rhodamine B, and Tannic Acid were added at 50 µM final concentration to inhibit Aß40 aggregation. Fluorescence was monitored at Ex/Em= 440/484 nm every 5 minutes at 37ºC with 15 seconds shaking between reads (Flexstation II-384 fluorimeter, Molecular Devices).
AD brain section probed with Ab (1-42), HiLyte™ Fluor 488 labeled peptide (Cat # AS-60479-01).
Image is courtesy of Dr. J-P Guo in Dr. Patrick L. McGeer's lab, University of British Columbia, Vancouver, Canada.
- Ready to use for direct fibrillation studies
- 더 나은 정확도를 위한 net Peptide quantities
- 높은 %의 monomeric state를 보장하기 위한 In-house proprietary pre-treatment
- 시간 절약 with our improved formulation
- High-impact journals에 인용
Application
- Amyloid aggregation 모니터링
- Amyloid aggregation kinetics
- Fibril 형성
- Amyloid inhibitor 스크리닝
Trending Citations
Cheng, Q. et al (2018). TREM2-activating antibodies abrogate the negative pleiotropic effects of the Alzheimer's disease variant TREM2(R47H) on murine myeloid cell function. J Biol Chrem 293(32):12620-12633. doi: 10.1074/jbc. RA118.001848.
Reinhardt, S. et al. (2018). Identification of disulfiram as a secretase-modulating compound with beneficial effects on Alzheimer's disease hallmarks. Sci Rep 8(1):1329. doi: 10.1038/s41598-018-19577-7.
Maneshi, MM. et al. (2018). Enantiomeric Aβ peptides inhibit the fluid shear stress response of PIEZO1. Sci Rep 8(1):14267. doi: 10.1038/s41598-018-32572-2.
Livadiotis, G. et al (2017). Experimental Analysis of Interacting HT22 Plasma Mrembrane Cholesterol and β-Amyloid. Advances in Alzheimer's Disease 6(04):75.
An, S. et al (2017). Dynamic changes of oligomeric amyloid β levels in plasma induced by spiked synthetic Aβ42. Alzheimers Res Ther 9:86. doi:10.1186/s13195-017-0310-6
Wang, M. et al (2017). Oligomeric forms of amyloid β protein in plasma as a potential blood-based biomarker for Alzheimer's disease. Alzheimers Res Ther 9:98. doi:10.1186/s13195-017-0324-0
Hartz. AM, et al. (2016). Aβ40 Reduces P-Glycoprotein at the Blood-Brain Barrier through the Ubiquitin-Proteasome Pathway. J Neurosci. 36(6):1930-41. doi:10.1523/JNEUROSCI.0350-15.2016.
*높은 수요로 인해 2017 년 8 월 15 일부터 몇몇 Beta-Amyloid peptide에 한에 함께 배송되던 1 % NH4OH solution은 더 이상 무료로 제공되지 않습니다.
제품사양
| Beta-Amyloid 1-42 Peptides | AS-24224 Beta-Amyloid (1-42), Human AS-20276, -5, -25 Beta-Amyloid (1-42), Human AS-60479-01 Beta-Amyloid (1-42), HiLyte™ Fluor 488-labeled, Human |
|---|---|
| Beta-Amyloid 1-40 Peptides | AS-24235 Beta-Amyloid (1-40), Human AS-24236, -5 Beta-Amyloid (1-40), Human AS-60491-01 Beta-Amyloid (1-40), HiLyte™ Fluor 488-labeled, Human |
| 1% NH4OH Solution Product Specifications | Catalog number: AS-61322 Molecular Weight: 35.05 Volume: 300 microliters |
주문정보
| Cat No. | 품명 | 규격 | 제조사 | 제품정보 | 수량 | 견적문의 | |
|---|---|---|---|---|---|---|---|
| AS-24224 | Beta-Amyloid (1-42), Human | 0.5 mg | Anaspec | Aß (1-42), a major component of amyloid plaques, accumulates in neurons of Alzheimer’s disease brains. Biochemical analysis of the amyloid peptides isolated from Alzheimer’s disease brain indicates that Aß (1-42) is the principal species associated with senile plaque amyloids, while Aß (1-40) is more abundant in cerebrovascular amyloid deposit. |   |
 카트담기 견적문의 |
|
| AS-62002-05 | Beta-Amyloid (1-15)-Lys16(HiLyte™ Fluor 488), Human | 0.5 mg | Anaspec | This peptide is the beta-Amyloid peptide, residues 1 to 16 labeled with HiLyte™ Fluor 488 on the Lys16, Abs/Em =501/527. | |
카트담기 견적문의 |
|
| AS-72071 | SensoLyte® Fluorescent ß-Amyloid (1-42) Sampler Kit, Human | 1 kit | Anaspec | Fluorophore labeled beta-amyloid peptides have been used in investigating beta-amyloid's aggregation, generation and clearance, microglial activation and phagocytosis. The SensoLyte® Fluorescent beta-Amyloid (1-42) Sampler Kit provides three fluorescent beta-amyloid (1-42) peptides, two unlabeled control peptides and biotin labeled beta-amyloid (1-42) peptide.. The sampler kit provides ample choices for researchers interested in beta-amyloid related experiments. | |
카트담기 견적문의 |
|
| AS-GMP-20276-1 | GMP beta-Amyloid (1-42), human (Ammonium Salt) | 1 mg NET peptide | Anaspec | This highly pure, well-characterized GMP beta-Amyloid (1-42) peptide has been produced under conditions compliant with 21 CFR part 820 and ISO 13485.Features & Benefits: Added Assurance for your high profile projects, Compliant with 21 CFR part 820 and ISO 13485, Manufactured in controlled areas under SOP's, BR's, with qualified equipment and staff, Lot to lot reproducibility, consistency, and traceability, Comprehensive QC Testing and characterizationApplications*Ideal for: In Vitro Diagnostics, QC Controls & Standards, Pre-Clinical animal studies. *Not to be used as an API in it's current form | |
카트담기 견적문의 |
|
| AS-GMP-20276-5 | GMP beta-Amyloid (1-42), human (Ammonium Salt) | 5 mg NET peptide | Anaspec | This highly pure, well-characterized GMP beta-Amyloid (1-42) peptide has been produced under conditions compliant with 21 CFR part 820 and ISO 13485.Features & Benefits: Added Assurance for your high profile projects, Compliant with 21 CFR part 820 and ISO 13485, Manufactured in controlled areas under SOP's, BR's, with qualified equipment and staff, Lot to lot reproducibility, consistency, and traceability, Comprehensive QC Testing and characterizationApplications*Ideal for: In Vitro Diagnostics, QC Controls & Standards, Pre-Clinical animal studies. *Not to be used as an API in it's current form | |
카트담기 견적문의 |
|
| AS-GMP-24236-1 | GMP beta-Amyloid (1-40), human (Ammonium Salt) | 1 mg NET peptide | Anaspec | This highly pure, well-characterized GMP beta-Amyloid (1-40) peptide has been produced under conditions compliant with 21 CFR part 820 and ISO 13485.Features & Benefits: Added Assurance for your high profile projects, Compliant with 21 CFR part 820 and ISO 13485, Manufactured in controlled areas under SOP's, BR's, with qualified equipment and staff, Lot to lot reproducibility, consistency, and traceability, Comprehensive QC Testing and characterizationApplications*Ideal for: In Vitro Diagnostics, QC Controls & Standards, Pre-Clinical animal studies. *Not to be used as an API in it's current form | |
카트담기 견적문의 |
|
| AS-GMP-24236-5 | GMP beta-Amyloid (1-40), human (Ammonium Salt) | 5 mg NET peptide | Anaspec | This highly pure, well-characterized GMP beta-Amyloid (1-40) peptide has been produced under conditions compliant with 21 CFR part 820 and ISO 13485.Features & Benefits: Added Assurance for your high profile projects, Compliant with 21 CFR part 820 and ISO 13485, Manufactured in controlled areas under SOP's, BR's, with qualified equipment and staff, Lot to lot reproducibility, consistency, and traceability, Comprehensive QC Testing and characterizationApplications*Ideal for: In Vitro Diagnostics, QC Controls & Standards, Pre-Clinical animal studies. *Not to be used as an API in it's current form | |
카트담기 견적문의 |
|
| AS-20276 | Beta-Amyloid (1-42), Human | 1 mg | Anaspec | Aß (1-42), a major component of amyloid plaques, accumulates in neurons of Alzheimer’s disease brains. Biochemical analysis of the amyloid peptides isolated from Alzheimer’s disease brain indicates that Aß (1-42) is the principal species associated with senile plaque amyloids, while Aß (1-40) is more abundant in cerebrovascular amyloid deposit. | |
카트담기 견적문의 |
|
| AS-20276-25 | Beta-Amyloid (1-42), Human | 25 mg | Anaspec | Aß (1-42), a major component of amyloid plaques, accumulates in neurons of Alzheimer’s disease brains. Biochemical analysis of the amyloid peptides isolated from Alzheimer’s disease brain indicates that Aß (1-42) is the principal species associated with senile plaque amyloids, while Aß (1-40) is more abundant in cerebrovascular amyloid deposit. | |
카트담기 견적문의 |
|
| AS-20276-5 | Beta-Amyloid (1-42), Human | 5 mg | Anaspec | Aß (1-42), a major component of amyloid plaques, accumulates in neurons of Alzheimer’s disease brains. Biochemical analysis of the amyloid peptides isolated from Alzheimer’s disease brain indicates that Aß (1-42) is the principal species associated with senile plaque amyloids, while Aß (1-40) is more abundant in cerebrovascular amyloid deposit. | |
카트담기 견적문의 |
|
| AS-20698 | Beta-Amyloid (1-40) • HCl, Human | 1 mg | Anaspec | All the HCl salt forms of Aß (1-40), Aß (25-35) and D-Ser26 Aß (25-35), take the ß-structure within a few hours in PBS. They form fibrils, exert toxic effects on hippocampal cultured neurons and suppress MTT reduction activity of non-neuronal (HeLa) cells without cytotoxicity. | |
카트담기 견적문의 |
|
| AS-21791 | Beta-Amyloid (1-42) • HCl, Human | 0.5 mg | Anaspec | Beta-Amyloid (1-42) and Related Peptides | |
카트담기 견적문의 |
|
| AS-21793 | Beta-Amyloid (1-42) • HCl, Human | 1 mg | Anaspec | Beta-Amyloid (1-42) and Related Peptides | |
카트담기 견적문의 |
|
| AS-22813 | Beta-Amyloid (17-40), Human, mouse/rat | 0.5 mg | Anaspec | Beta-Amyloid (1-40) and Related Peptides | |
카트담기 견적문의 |
|
| AS-22814 | Beta-Amyloid (17-40), Human, mouse/rat | 1 mg | Anaspec | Beta-Amyloid (1-40) and Related Peptides | |
카트담기 견적문의 |
|
| AS-22817 | Beta-Amyloid (40-1), Human | 0.5 mg | Anaspec | Beta-Amyloid Peptide Fragments | |
카트담기 견적문의 |
|
| AS-22818 | Beta-Amyloid (40-1), Human | 1 mg | Anaspec | Beta-Amyloid Peptide Fragments | |
카트담기 견적문의 |
|
| AS-22819 | Beta-Amyloid (1-11), Human | 1 mg | Anaspec | Anionic interaction of Aß(1-11) with Factor XII is suspected to cause the massive activation of the C4 (Complement 4) system in cerebrospinal fluid of Alzheimer’s disease patients. | |
카트담기 견적문의 |
|
| AS-22823 | Beta-Amyloid (22-35), Human, mouse/rat | 1 mg | Anaspec | Beta-Amyloid Peptide Fragments | |
카트담기 견적문의 |
|
| AS-23211 | Beta-Amyloid (1-40) • HCl, Human | 0.5 mg | Anaspec | All the HCl salt forms of Aß (1-40), Aß (25-35) and D-Ser26 Aß (25-35), take the ß-structure within a few hours in PBS. They form fibrils, exert toxic effects on hippocampal cultured neurons and suppress MTT reduction activity of non-neuronal (HeLa) cells without cytotoxicity. | |
카트담기 견적문의 |
|
| AS-23212 | Beta-Amyloid (25-35) • HCl, Human, mouse/rat | 5 mg | Anaspec | Beta-Amyloid Peptide Fragments | |
카트담기 견적문의 |
|
| AS-23512 | Biotin-beta-Amyloid (1-40), Human | 1 mg | Anaspec | Beta-Amyloid (1-40) and Related Peptides | |
카트담기 견적문의 |
|
| AS-23512-01 | Biotin-beta-Amyloid (1-40), Human | 0.1 mg | Anaspec | Beta-Amyloid (1-40) and Related Peptides | |
카트담기 견적문의 |
|
| AS-23513-05 | Beta-Amyloid (1-40), FAM-labeled, Human | 0.5 mg | Anaspec | This is a fluorescent (FAM)-labeled ß-Amyloid (1-40), Abs/Em=494/521 nm. FAM is preferred over FITC because of its photo- and chemical stability. | |
카트담기 견적문의 |
|
| AS-23514-01 | Beta-Amyloid (1-40), FAM-labeled, Human | 0.1 mg | Anaspec | This is a fluorescent (FAM)-labeled ß-Amyloid (1-40), Abs/Em=494/521 nm. FAM is preferred over FITC because of its photo- and chemical stability. | |
카트담기 견적문의 |
|
| AS-23517 | Beta-Amyloid (1-40)-Lys(Biotin-LC), Human | 0.5 mg | Anaspec | This C-terminal biotinylated Aß(1-40) contains a 6-carbon long chain (LC) to provide more accesibility for avidin attachment. | |
카트담기 견적문의 |
|
| AS-23518-01 | Beta-Amyloid (1-40)-Lys(Biotin-LC), Human | 0.1 mg | Anaspec | This C-terminal biotinylated Aß(1-40) contains a 6-carbon long chain (LC) to provide more accesibility for avidin attachment. | |
카트담기 견적문의 |
|
| AS-23520 | Cys-beta-Amyloid (1-40), Human | 1 mg | Anaspec | Beta-Amyloid (1-40) and Related Peptides | |
카트담기 견적문의 |
|
| AS-23523-05 | Biotin-beta-Amyloid (1-42), Human | 0.5 mg | Anaspec | Beta-Amyloid (1-42) and Related Peptides | |
카트담기 견적문의 |
|
| AS-23524-01 | Biotin-beta-Amyloid (1-42), Human | 0.1 mg | Anaspec | Beta-Amyloid (1-42) and Related Peptides | |
카트담기 견적문의 |
|
| AS-23525-05 | Beta-Amyloid (1-42), FAM-labeled, Human | 0.5 mg | Anaspec | This is a fluorescent (FAM)-labeled ß-Amyloid peptide, Abs/Em=494/521 nm. | |
카트담기 견적문의 |
|
| AS-23526-01 | Beta-Amyloid (1-42), FAM-labeled, Human | 0.1 mg | Anaspec | This is a fluorescent (FAM)-labeled ß-Amyloid peptide, Abs/Em=494/521 nm. | |
카트담기 견적문의 |
|
| AS-23537 | Cys-beta-Amyloid (1-42), Human | 0.5 mg | Anaspec | Beta-Amyloid (1-42) and Related Peptides | |
카트담기 견적문의 |
|
| AS-23538 | Cys-beta-Amyloid (1-42), Human | 1 mg | Anaspec | Beta-Amyloid (1-42) and Related Peptides | |
카트담기 견적문의 |
|
| AS-23541 | Biotin-beta-Amyloid (17-40), Human, mouse/rat | 1 mg | Anaspec | Beta-Amyloid (1-40) and Related Peptides | |
카트담기 견적문의 |
|
| AS-23956 | Beta-Amyloid (11-22), Human | 1 mg | Anaspec | Beta-Amyloid Peptide Fragments | |
카트담기 견적문의 |
|
| AS-24225 | Beta-Amyloid (1-16), Human | 1 mg | Anaspec | Proteins interactions with reactive oxygen agents may result in covalent modifications of amino acid residues in proteins, formation of protein-protein cross-linkages and oxidation of the protein backbone resulting in protein fragmentation. Oxidation targets for Aß(1-16) are the histidine residues coordinated to the metal ions. Copper is bound to Aß in senile plaque of Alzheimer’s disease with Aß (1-16) taking part in the coordination of the Cu2+ ions. Cu2+ and Zn2+ are linked with the neurotoxicity of Aß and free radical damage. | |
카트담기 견적문의 |
|
| AS-24226 | Beta-Amyloid (1-16), Human | 5 mg | Anaspec | Proteins interactions with reactive oxygen agents may result in covalent modifications of amino acid residues in proteins, formation of protein-protein cross-linkages and oxidation of the protein backbone resulting in protein fragmentation. Oxidation targets for Aß (1-16) are the histidine residues coordinated to the metal ions. Copper is bound to Aß in senile plaque of Alzheimer’s disease with Aß (1-16) taking part in the coordination of the Cu2+ ions. Cu2+ and Zn2+ are linked with the neurotoxicity of Aß and free radical damage. | |
카트담기 견적문의 |
|
| AS-24227 | Beta-Amyloid (25-35), Human, mouse/rat | 1 mg | Anaspec | Aß (25-35) is the main factor responsible for Aß neurotoxic effects. | |
카트담기 견적문의 |
|
| AS-24228 | Beta-Amyloid (25-35), Human, mouse/rat | 5 mg | Anaspec | Aß (25-35) is the main factor responsible for Aß neurotoxic effects. | |
카트담기 견적문의 |
|
| AS-24229 | Beta-Amyloid (12-28), Human | 0.5 mg | Anaspec | Aß (12–28) residues are the binding site for apolipoprotein E (apoE) on Aß. This sequence encompasses a hydrophobic domain (residues 14–21) and a ß-turn (residues 22–28) which place two hydrophobic domains of Aß 14 to 21 and 29 to 40/42 opposite each other, allowing for the assembly of Aß peptides into fibrils. The secondary structure of Aß (12- 28), a neutral peptide, is dominated by a-helix and random coil. The interaction of apoE with residues 12 to 28 of Aß is not just a non-specific hydrophobic interaction but plays a pivotal role in the mechanism of Aß pathology in Alzheimer’s disease (AD). Aß (11-28) and five other fragments enhanced aggregation of full length Aß (1-40). All of the peptides that enhance aggregation contained either residues 17 to 20 or 30 to 35, indicating the importance of these regions for promoting aggregation of full-length Aß. | |
카트담기 견적문의 |
|
| AS-24230 | Beta-Amyloid (12-28), Human | 1 mg | Anaspec | Aß (12–28) residues are the binding site for apolipoprotein E (apoE) on Aß. This sequence encompasses a hydrophobic domain (residues 14–21) and a ß-turn (residues 22–28) which place two hydrophobic domains of Aß 14 to 21 and 29 to 40/42 opposite each other, allowing for the assembly of Aß peptides into fibrils. The secondary structure of Aß (12- 28), a neutral peptide, is dominated by a-helix and random coil. The interaction of apoE with residues 12 to 28 of Aß is not just a non-specific hydrophobic interaction but plays a pivotal role in the mechanism of Aß pathology in Alzheimer’s disease (AD). Aß (11-28) and five other fragments enhanced aggregation of full length Aß (1-40). All of the peptides that enhance aggregation contained either residues 17 to 20 or 30 to 35, indicating the importance of these regions for promoting aggregation of full-length Aß. | |
카트담기 견적문의 |
|
| AS-24231 | Beta-Amyloid (1-28), Human | 0.5 mg | Anaspec | The three-dimensional solution structure of Aß (1-28) reveals the folding of the peptide to form a predominantly a-helical structure with a bend centered at residue 12 and the side chains of histidine-13 and lysine-16 in close proximity, residing on the same face of the helix. Their proximity may constitute a binding motif with the heparan sulfate proteoglycans. Aß (1-28) is highly hydrophilic and shares sequences with bA4, the major component of Aß. Its assembly is fibrillar, i.e., elongated in a single direction. Reports show that synthetic peptides Aß (1-40) and Aß (1-28) have significant effects on normal human plasma cholesterol esterification rate. Both peptides (at concentration of 1 ng/mL) inhibit plasma cholesterol esterification rate by 40-50% compared to the control value. | |
카트담기 견적문의 |
|
| AS-24232 | Beta-Amyloid (1-28), Human | 1 mg | Anaspec | The three-dimensional solution structure of Aß (1-28) reveals the folding of the peptide to form a predominantly a-helical structure with a bend centered at residue 12 and the side chains of histidine-13 and lysine-16 in close proximity, residing on the same face of the helix. Their proximity may constitute a binding motif with the heparan sulfate proteoglycans. Aß (1-28) is highly hydrophilic and shares sequences with bA4, the major component of Aß. Its assembly is fibrillar, i.e., elongated in a single direction. Reports show that synthetic peptides Aß (1-40) and Aß (1-28) have significant effects on normal human plasma cholesterol esterification rate. Both peptides (at concentration of 1 ng/mL) inhibit plasma cholesterol esterification rate by 40-50% compared to the control value. | |
카트담기 견적문의 |
|
| AS-24232-5 | Beta-Amyloid (1-28), Human | 5 mg | Anaspec | The three-dimensional solution structure of Aß (1-28) reveals the folding of the peptide to form a predominantly a-helical structure with a bend centered at residue 12 and the side chains of histidine-13 and lysine-16 in close proximity, residing on the same face of the helix. Their proximity may constitute a binding motif with the heparan sulfate proteoglycans. Aß (1-28) is highly hydrophilic and shares sequences with bA4, the major component of Aß. Its assembly is fibrillar, i.e., elongated in a single direction. Reports show that synthetic peptides Aß (1-40) and Aß (1-28) have significant effects on normal human plasma cholesterol esterification rate. Both peptides (at concentration of 1 ng/mL) inhibit plasma cholesterol esterification rate by 40-50% compared to the control value. | |
카트담기 견적문의 |
|
| AS-24233 | Beta-Amyloid (1-38), Human | 0.5 mg | Anaspec | Beta-Amyloid Peptide Fragments | |
카트담기 견적문의 |
|
| AS-24234 | Beta-Amyloid (1-38), Human | 1 mg | Anaspec | Beta-Amyloid Peptide Fragments | |
카트담기 견적문의 |
|
| AS-24235 | Beta-Amyloid (1-40), Human | 0.5 mg | Anaspec | Aß (1-40) together with Aß (1-42) are two major C-terminal variants of the Aß protein constituting the majority of Aßs. These undergo post-secretory aggregation and deposition in the Alzheimer’s disease brain. | |
카트담기 견적문의 |
|
| AS-24236 | Beta-Amyloid (1-40), Human | 1 mg | Anaspec | Aß (1-40) together with Aß (1-42) are two major C-terminal variants of the Aß protein constituting the majority of Aßs. These undergo post-secretory aggregation and deposition in the Alzheimer’s disease brain. | |
카트담기 견적문의 |
|
| AS-24236-5 | Beta-Amyloid (1-40), Human | 5 mg | Anaspec | Aß (1-40) together with Aß (1-42) are two major C-terminal variants of the Aß protein constituting the majority of Aßs. These undergo post-secretory aggregation and deposition in the Alzheimer’s disease brain. | |
카트담기 견적문의 |
|
| AS-24295 | Beta-Amyloid (1-39), Human | 0.5 mg | Anaspec | A number of Aß protein variants, differing only at their carboxy terminus (1-39, 1-40, 1-42 and 1-43), are identified as the major components of the cerebral amyloid deposits in Alzheimer’s disease. The length of the C-terminus is a critical determinant of the rate of amyloid formation (“kinetic solubility”), with only a minor effect on the thermodynamic solubility. Amyloid formation by the kinetically soluble peptides (e.g. 1-39) can be nucleated, or “seeded” by peptides which include the critical C-terminal residues (1-42, 26-42, 26-43, 34-42). | |
카트담기 견적문의 |
|
| AS-24296 | Beta-Amyloid (1-39), Human | 1 mg | Anaspec | A number of Aß protein variants, differing only at their carboxy terminus (1-39, 1-40, 1-42 and 1-43), are identified as the major components of the cerebral amyloid deposits in Alzheimer’s disease. The length of the C-terminus is a critical determinant of the rate of amyloid formation (“kinetic solubility”), with only a minor effect on the thermodynamic solubility. Amyloid formation by the kinetically soluble peptides (e.g. 1-39) can be nucleated, or “seeded” by peptides which include the critical C-terminal residues (1-42, 26-42, 26-43, 34-42). | |
카트담기 견적문의 |
|
| AS-24625 | Scrambled-beta-Amyloid (1-40), Human | 0.5 mg | Anaspec | Beta-Amyloid (1-40) and Related Peptides | |
카트담기 견적문의 |
|
| AS-24626 | Scrambled-beta-Amyloid (1-40), Human | 1 mg | Anaspec | Beta-Amyloid (1-40) and Related Peptides | |
카트담기 견적문의 |
|
| AS-24640 | Biotin-LC-beta-Amyloid (1-42), Human | 0.5 mg | Anaspec | This biotinylated Aß(1-42) contains an 6-carbon long chain (LC) to provide more accessibility for avidin attachment. | |
카트담기 견적문의 |
|
| AS-24641-01 | Biotin-LC-beta-Amyloid (1-42), Human | 0.1 mg | Anaspec | This biotinylated Aß(1-42) contains an 6-carbon long chain (LC) to provide more accessibility for avidin attachment. | |
카트담기 견적문의 |
|
| AS-24645 | Biotin-LC-beta-Amyloid (1-40), Human | 1 mg | Anaspec | This biotinylated Aß(1-40) contains a 6-carbon long chain (LC) to provide more accesibility for avidin attachment. | |
카트담기 견적문의 |
|
| AS-24645-01 | Biotin-LC-beta-Amyloid (1-40), Human | 0.1 mg | Anaspec | This biotinylated Aß(1-40) contains a 6-carbon long chain (LC) to provide more accesibility for avidin attachment. | |
카트담기 견적문의 |
|
| AS-24648 | Biotin-LC-beta-Amyloid (1-40), Human | 0.5 mg | Anaspec | This biotinylated Aß(1-40) contains a 6-carbon long chain (LC) to provide more accesibility for avidin attachment. | |
카트담기 견적문의 |
|
| AS-25230 | Beta-Amyloid Peptide (1-40), mouse, rat | 1 mg | Anaspec | Beta-Amyloid Peptides - Mouse/Rat | |
카트담기 견적문의 |
|
| AS-25231 | Beta-Amyloid Peptide (1-42), mouse, rat | 1 mg | Anaspec | Beta-Amyloid Peptides - Mouse/Rat | |
카트담기 견적문의 |
|
| AS-25356 | Beta-Amyloid (1-43), Human | 0.5 mg | Anaspec | Solid Aß (1-43) fibril is the most fibrillogenic of all the Aß peptides known. | |
카트담기 견적문의 |
|
| AS-25357 | Beta-Amyloid (1-43), Human | 1 mg | Anaspec | Solid Aß (1-43) fibril is the most fibrillogenic of all the Aß peptides known. | |
카트담기 견적문의 |
|
| AS-25365 | Beta-Amyloid (10-20), Human | 1 mg | Anaspec | A number of Aß fragments including Aß (10-20) enhances aggregation of Aß (1-40). All the Aß peptides that enhance aggregation contain either residues 17 to 20 or 30 to 35, indicating the importance of these regions for promoting aggregation of full-length Aß. | |
카트담기 견적문의 |
|
| AS-25380 | Beta-Amyloid Peptide (1-40), mouse, rat | 0.5 mg | Anaspec | Beta-Amyloid Peptides - Mouse/Rat | |
카트담기 견적문의 |
|
| AS-25381 | Beta-Amyloid Peptide (1-42), mouse, rat | 0.5 mg | Anaspec | Beta-Amyloid Peptides - Mouse/Rat | |
카트담기 견적문의 |
|
| AS-25382 | Scrambled-beta-Amyloid (1-42), Human | 0.5 mg | Anaspec | Beta-Amyloid (1-42) and Related Peptides | |
카트담기 견적문의 |
|
| AS-25383 | Scrambled-beta-Amyloid (1-42), Human | 1 mg | Anaspec | Beta-Amyloid (1-42) and Related Peptides | |
카트담기 견적문의 |
|
| AS-27275 | Beta-Amyloid (42-1), Human | 0.5 mg | Anaspec | Beta-Amyloid (1-42) and Related Peptides | |
카트담기 견적문의 |
|
| AS-27276 | Beta-Amyloid (42-1), Human | 1 mg | Anaspec | Beta-Amyloid (1-42) and Related Peptides | |
카트담기 견적문의 |
|
| AS-27276-01 | Beta-Amyloid (42-1), Human | 0.1 mg | Anaspec | Beta-Amyloid (1-42) and Related Peptides | |
카트담기 견적문의 |
|
| AS-29903-01 | [Pyr11]-beta-Amyloid (11-42), Human | 0.1 mg | Anaspec | Aßs are generated by the proteolytic processing of the amyloid ß-precursor protein (APP). Subsequent cleavage by g-secretase gives rise to Aß (1-40/42) and Aß (11-40/42). Aß (11-40) and Aß (11-42) are major Aß cleavage products generated by BACE. | |
카트담기 견적문의 |
|
| AS-29903-1 | [Pyr11]-beta-Amyloid (11-42), Human | 1 mg | Anaspec | Aßs are generated by the proteolytic processing of the amyloid ß-precursor protein (APP). Subsequent cleavage by g-secretase gives rise to Aß (1-40/42) and Aß (11-40/42). Aß (11-40) and Aß (11-42) are major Aß cleavage products generated by BACE. | |
카트담기 견적문의 |
|
| AS-29904-1 | [Pyr11]-beta-Amyloid (11-40), Human | 1 mg | Anaspec | Beta-Amyloid (1-40) and Related Peptides | |
카트담기 견적문의 |
|
| AS-29905-1 | Beta-Amyloid (2-40), Human | 1 mg | Anaspec | Beta-Amyloid (1-40) and Related Peptides | |
카트담기 견적문의 |
|
| AS-29906-01 | [Pyr3]-beta-Amyloid (3-40), Human | 0.1 mg | Anaspec | This peptide triggers the formation of insoluble Aß peptide deposits, inhibits secretion of amyloid protein precursor (APP) and increases cell-associated APP. The fibrils in the plaques formed in the brains of patients with Alzheimer’s disease contain significant amounts of truncated Aß proteins such as Aß(3-40) and Aß (11- 40). These two fragments contain an N-terminal pyroglutamic acid. The g-carboxy group of glutamic acid forms a cyclic bond with the free N-terminal amino group to form pyroglutamate. | |
카트담기 견적문의 |
|
| AS-29906-1 | [Pyr3]-beta-Amyloid (3-40), Human | 1 mg | Anaspec | This peptide triggers the formation of insoluble Aß peptide deposits, inhibits secretion of amyloid protein precursor (APP) and increases cell-associated APP. The fibrils in the plaques formed in the brains of patients with Alzheimer’s disease contain significant amounts of truncated Aß proteins such as Aß(3-40) and Aß (11- 40). These two fragments contain an N-terminal pyroglutamic acid. The g-carboxy group of glutamic acid forms a cyclic bond with the free N-terminal amino group to form pyroglutamate. | |
카트담기 견적문의 |
|
| AS-29907-01 | [Pyr3]-beta-Amyloid (3-42), Human | 0.1 mg | Anaspec | This is one of the predominant amyloid peptide structures deposited in human brain of Alzheimer’s disease and Down’s syndrome patients. | |
카트담기 견적문의 |
|
| AS-29907-1 | [Pyr3]-beta-Amyloid (3-42), Human | 1 mg | Anaspec | This is one of the predominant amyloid peptide structures deposited in human brain of Alzheimer’s disease and Down’s syndrome patients. | |
카트담기 견적문의 |
|
| AS-29908-1 | Beta-Amyloid (4-42), Human | 1 mg | Anaspec | Beta-Amyloid (1-42) and Related Peptides | |
카트담기 견적문의 |
|
| AS-29909-01 | Beta-Amyloid (2-42), Human | 0.1 mg | Anaspec | Beta-Amyloid (1-42) and Related Peptides | |
카트담기 견적문의 |
|
| AS-29909-1 | Beta-Amyloid (2-42), Human | 1 mg | Anaspec | Beta-Amyloid (1-42) and Related Peptides | |
카트담기 견적문의 |
|
| AS-60017-1 | Beta-Amyloid (11-40), Human | 1 mg | Anaspec | Post-mortem Alzheimer’s diseased brain specimens reveals significant levels of Aß (11-40/42) within insoluble amyloid pools. The ß-secretaseEnzyme or ß-amyloid precursor protein-cleavingEnzyme (BACE) generates the N terminus of Aß, ultimately leading to the production of full-length Aß (1-40/42) or truncated Aß (11-40/42). The abundance of Aß (11-40/42) produced by BACE suggests that their roles in AD pathogenesis may be important. | |
카트담기 견적문의 |
|
| AS-60084-1 | Beta-Amyloid (9-42), Human | 1 mg | Anaspec | Beta-Amyloid (1-42) and Related Peptides | |
카트담기 견적문의 |
|
| AS-60087-01 | Beta-Amyloid (5-42), Human | 0.1 mg | Anaspec | Beta-Amyloid (1-42) and Related Peptides | |
카트담기 견적문의 |
|
| AS-60087-1 | Beta-Amyloid (5-42), Human | 1 mg | Anaspec | Beta-Amyloid (1-42) and Related Peptides | |
카트담기 견적문의 |
|
| AS-60250-1 | Beta-Amyloid (1-33), Human | 1 mg | Anaspec | Purified metalloendopeptidase cleaves the Gly33-Leu34 bond of Alzheimer Aß (1-40) peptide producing soluble 1-33 and 34-40 fragments of Aß (1-40) without any neurotoxic effects. | |
카트담기 견적문의 |
|
| AS-60251-05 | Beta-Amyloid (1-37), Human | 0.5 mg | Anaspec | Beta-Amyloid Peptide Fragments | |
카트담기 견적문의 |
|
| AS-60251-1 | Beta-Amyloid (1-37), Human | 1 mg | Anaspec | Beta-Amyloid Peptide Fragments | |
카트담기 견적문의 |
|
| AS-60252-05 | Beta-Amyloid (1-36), Human | 0.5 mg | Anaspec | Beta-Amyloid Peptide Fragments | |
카트담기 견적문의 |
|
| AS-60476 | Beta-Amyloid (1-42), TAMRA-labeled, Human | 0.1 mg | Anaspec | Beta-Amyloid (1-42) and Related Peptides | |
카트담기 견적문의 |
|
| AS-60479-01 | Beta-Amyloid (1-42), HiLyte™ Fluor 488-labeled, Human | 0.1 mg | Anaspec | This is a fluorescent (HiLyte™ Fluor 488)-labeled ß-Amyloid peptide, Abs/Em=503/528 nm. Hilyte 488™ Fluor labeled Aß (1-42) has a brighter intensity than FAM-labeled Aß (1-42). | |
카트담기 견적문의 |
|
| AS-60480-01 | Beta-Amyloid (1-42), HiLyte™ Fluor 555-labeled, Human | 0.1 mg | Anaspec | This is a fluorescent (HiLyte™ Fluor 555)-labeled ß-Amyloid peptide, Abs/Em=551/567 nm. | |
카트담기 견적문의 |
|
| AS-60488-01 | Beta-Amyloid (1-40), TAMRA-labeled, Human | 0.1 mg | Anaspec | This is a fluorescent (TAMRA)-labeled ß-Amyloid peptide, Abs/Em=544/572 nm. | |
카트담기 견적문의 |
|
| AS-60491-01 | Beta-Amyloid (1-40), HiLyte™ Fluor 488-labeled, Human | 0.1 mg | Anaspec | This is a fluorescent (HiLyte™ Fluor 488)-labeled ß-Amyloid peptide, Abs/Em=503/528 nm. | |
카트담기 견적문의 |
|
| AS-60492-01 | Beta-Amyloid (1-40), HiLyte™ Fluor 555-labeled, Human | 0.1 mg | Anaspec | This is a fluorescent (HiLyte™ Fluor 555)-labeled ß-Amyloid peptide, Abs/Em=551/567 nm. HiLyte™ Fluor 555 labeled Aß (1-40) is more photostable than Cy3®-labeled Aß (1-40). | |
카트담기 견적문의 |
|
| AS-60493 | Beta-Amyloid (1-40), HiLyte™ Fluor 647-labeled, Human | 0.1 mg | Anaspec | Beta-Amyloid (1-40) and Related Peptides | |
카트담기 견적문의 |
|
| AS-60883 | Beta-Amyloid (1-42), sodium salt, Human | 1 mg | Anaspec | This peptide prepared by neutralizing the TFA salt form of Aß (1-42) with a dilute sodium hydroxide solution has superior solubility and fibrillogenesis properties, and the fibrils are equally neurotoxic. | |
카트담기 견적문의 |
|
| AS-60883-01 | Beta-Amyloid (1-42), sodium salt, Human | 0.1 mg | Anaspec | This peptide prepared by neutralizing the TFA salt form of Aß (1-42) with a dilute sodium hydroxide solution has superior solubility and fibrillogenesis properties, and the fibrils are equally neurotoxic. | |
카트담기 견적문의 |
|
| AS-60892 | Beta-Amyloid (1-42), Scrambled, 5-FAM labeled, Human | 0.1 mg | Anaspec | Beta-Amyloid (1-42) and Related Peptides | |
카트담기 견적문의 |
|
| AS-61029 | Beta-Amyloid (3-40), Human | 0.1 mg | Anaspec | Beta-Amyloid (1-40) and Related Peptides | |
카트담기 견적문의 |
|
| AS-61261 | [Gln22]-beta-Amyloid (1-40), Dutch Mutation, Human | 0.5 mg | Anaspec | Beta-Amyloid (1-40) and Related Peptides | |
카트담기 견적문의 |
|
| AS-61262 | [Gly22]-beta-Amyloid (1-40), Arctic Mutation, Human | 0.5 mg | Anaspec | Beta-Amyloid (1-40) and Related Peptides | |
카트담기 견적문의 |
|
| AS-61483-01 | Beta-Amyloid (1-40)-Lys(Biotin)-NH2, Human | 0.1 mg | Anaspec | The difference between this recently released and the previous product (Cat# 23515) is the change at the C terminus from a carboxylic acid to an amide. The biological activity should remain the same. | |
카트담기 견적문의 |
|
| AS-61483-05 | Beta-Amyloid (1-40)-Lys(Biotin)-NH2, Human | 0.5 mg | Anaspec | The difference between this recently released and the previous product (Cat# 23515) is the change at the C terminus from a carboxylic acid to an amide. The biological activity should remain the same. | |
카트담기 견적문의 |
|
| AS-61484-01 | Beta-Amyloid (1-42)-Lys(Biotin)-NH2, Human | 0.1 mg | Anaspec | The difference between this recently released and the previous product (Cat# 23528-01) is the change at the C terminus from a carboxylic acid to an amide. The biological activity should remain the same. | |
카트담기 견적문의 |
|
| AS-61484-05 | Beta-Amyloid (1-42)-Lys(Biotin)-NH2, Human | 0.5 mg | Anaspec | The difference between this recently released and the previous product (Cat# 23527) is the change at the C terminus from a carboxylic acid to an amide. The biological activity should remain the same. | |
카트담기 견적문의 |
|
| AS-61798 | Beta-Amyloid (1-15), Human | 1 mg | Anaspec | Beta-Amyloid Peptide Fragments | |
카트담기 견적문의 |
|
| AS-61799 | Beta-Amyloid (1-34), Human | 0.5 mg | Anaspec | Beta-Amyloid Peptide Fragments | |
카트담기 견적문의 |
|
| AS-61802 | Beta-Amyloid (13-28), Human | 1 mg | Anaspec | This β-Amyloid peptide 13 to 27 amino acid residues was used to study the kinetics of β-amyloid formation. | |
카트담기 견적문의 |
|
| AS-61937 | [NMeG24, NMeI26] Human Islet Amyloid Polypeptide (IAPP) (22 - 27) | 1 mg | Anaspec | This amino acids 22 to 27 fragment is a modification of the human islet amyloid polypeptide hIAPP (NFGAIL) with N-methylation of the amide bonds at G24 and I26. The introduction of two N-methyl rests in the amyloid-core-containing sequence NFGAIL converts this amyloidogenic and cytotoxic sequence into non-amyloidogenic and non-cytotoxic peptide. The peptide is able to bind with high-affinity full-length hIAPP and to inhibit its fibrillogenesis. | |
카트담기 견적문의 |
|
| AS-61955 | Beta-Amyloid (1-17), Human | 1 mg | Anaspec | This is beta-Amyloid peptide fragment derived from amino acids 1 to 17. This peptide was employed in the b-Amyloid solubility studies. | |
카트담기 견적문의 |
|
| AS-61962-01 | Beta-Amyloid (1-40)-Lys(LC-biotin)-NH2, FAM-labeled, Human | 0.1 mg | Anaspec | This is a 5-FAM labeled ß-?Amyloid (1-40). This amidated peptide is also biotinylated on the lysine side chain with 6-aminohexanoate (LC) as a spacer, Ex/Em=490 nm/ 520 nm. | |
카트담기 견적문의 |
|
| AS-61967-05 | [Gly22]-beta-Amyloid (1-42), E22G Arctic Mutation, Human | 0.5 mg | Anaspec | This is amino acids 1 to 40 fragment of the mutant form of beta-amyloid, with glycine substituted for glutamic acid at position 22 found in “Arctic” heredity. A toxic soluble beta-amyloid assembly (TA-beta) is formed more rapidly from 'Arctic' beta-amyloid than from wild-type beta-amyloid in the presence of liposomes containing GM1 ganglioside. | |
카트담기 견적문의 |
|
| AS-61970 | Beta-Amyloid (1-9), Human | 1 mg | Anaspec | This is the N-terminal fragment of b-Amyloid peptide amino acids 1 to 9. Omission of residues 1 to 9 from the full-length Alzheimer's b-Amyloid peptide 1 to 40 does not prevent the peptide from forming amyloid fibrils or eliminate fibril polymorphism. This b-Amyloid peptide fragment contains a functional B cell epitope, but lacks known T cell epitopes, which makes it an attractive candidate for the development of b-Amyloid vaccine that lacks the potential to induce autoimmune encephalitis. | |
카트담기 견적문의 |
|
| AS-61971 | Beta-Amyloid (25-35), scrambled, Human, mouse/rat | 1 mg | Anaspec | This is the scrambled beta-Amyloid peptide amino acids 25 to 35. Pairing this peptide with the native b-Amyloid 25 to 35 amino acids peptide has been used to recognize its structure and functions. | |
카트담기 견적문의 |
|
| AS-61972 | Beta-Amyloid (22-42), Human, mouse/rat | 1 mg | Anaspec | This is the hydrophobic C-terminal fragment of b-Amyloid peptide amino acids 22 to 42. | |
카트담기 견적문의 |
|
| AS-61978 | Beta-Amyloid (17-24), Human, mouse/rat | 1 mg | Anaspec | This peptide is b-Amyloid 17 to 24 amino acids fragment. Several lines of evidence indicate that a region centering around positions 17 to 20 amino acids is important for b-Amyloid fibril formation. Destabilization of a helix covering residues 11–24, in particular residues 17–24, is critical for alpha-helix to b-strand conversion and fibril formation. | |
카트담기 견적문의 |
|
| AS-61989 | Beta-Amyloid (20-42), Human, mouse/rat | 1 mg | Anaspec | This synthetic peptide corresponds to amino acids 20 to 42 of b-Amyloid protein. | |
카트담기 견적문의 |
|
| AS-62073 | Beta-Amyloid A4 Protein Precursor (740-770), APP (C31) | 1 mg | Anaspec | This 31-amino acid peptide C31 corresponds to the C-terminal fragment of the Amyloid Precursor Protein (APP). Caspase cleavage of amyloid beta-protein precursor with the generation of C31 may be involved in the neuronal death associated with Alzheimer disease. The resultant C31 peptide is a potent inducer of apoptosis. This peptide is located in lipid rafts together with the APP-BP1, a binding protein for the intracellular domain of APP. | |
카트담기 견적문의 |
|
| AS-62136 | Beta-Amyloid (1-16)-Lys(Biotin-LC)-NH2, Human | 1 mg | Anaspec | This is a C-terminal Lys(Biotin-LC) modified b-Amyloid peptide, residues 1 to 17. 6-aminohexanoate (LC) is used as a spacer. | |
카트담기 견적문의 |
|
| AS-62142 | [Gln22]-beta-Amyloid (1-42), E22Q Dutch Mutation, Human | 0.5 mg | Anaspec | This peptide is a naturally occurring mutant form of the wild type (WT) beta-Amyloid 1 to 42 peptide. The E22Q 'Dutch' mutant, also known as HCHWA-D, is caused by a point mutation in the beta-Amyloid encoding gene, with Glu replaced by Gln at position 22. Dutch E22Q mutation in beta-Amyloid causes familial cerebrovascular amyloidosis with abundant diffused amyloid plaque deposits. E22Q mutant and WT peptides are both stable in 'collapsed coil' conformations. The E22Q fibrils are more toxic for vascular cells than the WT fibrils. | |
카트담기 견적문의 |
|
| AS-62145 | [Asn23]-beta-Amyloid (1-40), Iowa Mutation, Human | 0.5 mg | Anaspec | This peptide is naturally occurring mutant within the beta-amyloid region of b-amyloid protein precursor (APP). This mutation is associated with severe cerebral amyloid beta-protein angiopathy (CAA) in Iowa kindred. The affected individuals share a missense mutation in APP at position 694. This site corresponds to residue 23 of beta-amyloid peptide resulting in substitution of asparagine for aspartic acid. | |
카트담기 견적문의 |
|
| AS-62146 | [Gln22, Asn23]-beta-Amyloid (1-40), E22Q/D23N Dutch/Iowa double mutation, Human | 0.5 mg | Anaspec | This peptide is the mutant form of beta-Amyloid 1 to 40. These mutations within the beta-Amyloid precursor protein (APP) regions result in the substitution of glutamine for glutamic acid and asparagine for aspartic acid. The peptide rapidly assembles in solution to form fibrils compared to the wild-type beta-Amyloid 1 to 40. Double-mutant E22Q/D23N Dutch/Iowa beta-Amyloid 40 is more potent than either of the single mutant form in causing pathologic responses in culture cells. The double mutations further enhances the fibrillogenic and pathogenic properties of beta-Amyloid. | |
카트담기 견적문의 |
|
| AS-62147 | [Lys22]-beta-Amyloid (1-40), Italian Mutation, Human | 0.5 mg | Anaspec | This is amino acids 1 to 40 fragment of the beta-amyloid peptide with lysine substituted for glutamic acid at position 22, found in Italian families. The Italian mutation of beta-amyloid 1-40 (E22K) aggregates more rapidly and with more potent neurotoxicity than wild-type beta-amyloid 1-40. The formation of a salt bridge between Lys-22 and Asp-23 in the minor conformer might be a reason why E22K-beta-amyloid 40 is more pathogenic than wild-type beta-amyloid 40. | |
카트담기 견적문의 |
|
| AS-62148 | [Lys22]-beta-Amyloid (1-42), Italian Mutation, Human | 0.5 mg | Anaspec | This is amino acids 1 to 42 fragment of the beta-amyloid peptide, with lysine substituted for glutamic acid at position 22 found in Italian families with Alzheimer's disease. The Italian mutation of beta -amyloid 1 to 42 (E22K) aggregates more rapidly and with more potent neurotoxicity than wild-type beta-amyloid (1-42). The formation of a salt bridge between Lys22 and Asp23 in the minor conformer might be a reason why E22K is more pathogenic than wild-type beta-amyloid (1-42). | |
카트담기 견적문의 |
|
| AS-62150 | [Gly21]-beta-Amyloid (1-40), A21G, Flemish Mutation, Human | 0.5 mg | Anaspec | This peptide is the mutant form of the b-Amyloid peptide (1-40). The mutation within the coding region of the ß-Amyloid precursor protein (APP) results in substitution of glycine for alanine in this peptide. Presenile dementia is present in a pattern consistent in the family of British origin with the dominant inheritance of Flemish APP mutation. The impact of the point mutation A21G on b-Amyloid structure and dynamics varies from b-Amyloid (1-40) to b-Amyloid (1-42). | |
카트담기 견적문의 |
|
| AS-62233 | Beta-Amyloid (1-40)-Cys, Human | 0.1 mg | Anaspec | This synthetic peptide corresponds to ß--Amyloid (1-40) with an additional cysteine at the C-terminus. | |
카트담기 견적문의 |
|
| AS-62427 | Beta-Amyloid (1-40) Binding Peptide, Biotin-labeled | 1 mg | Anaspec | This 20 amino acid peptide binds to the amyloid form of beta-Amyloid (1-40) but not to monomeric beta-Amyloid (1-40). This sequence represents new potential carrier molecules to deliver medicines to amyloid plaques in AD patients and to image plaques in AD brains. The ability to directly target reagents to the amyloid form of the beta-Amyloid peptide may allow the delivery of neuroprotective agents to make amyloid plaques less toxic, the delivery of amyloid-destroying molecules to eliminate plaques, or the delivery of reagents to prevent amyloid plaque formation. This sequence is biotinylated on the N-terminus. | |
카트담기 견적문의 |
|
| AS-62447 | Beta-Amyloid (17-28), Human, mouse/rat | 1 mg | Anaspec | This peptide is amino acids 17 to 28 fragment of beta-amyloid. | |
카트담기 견적문의 |
|
| AS-62451 | Biotin-beta-Amyloid (25-35), Human, mouse/rat | 1 mg | Anaspec | This peptide is amino acids 25 to 35 fragment of the ß-amyloid biotinylated at C-terminus. This peptide possesses many of the characteristics of the full-length ß-amyloid peptide, including an amphiphilic nature and an ability to aggregate, and can serve as a model system to study the conformational changes involved in Alzheimer's disease. Aggregates of ß-amyloid (25–35) have been shown to possess the neurotrophic and neurotoxic properties of their full-length counterparts and there is evidence that the monomeric form of the peptide may itself be cytotoxic. | |
카트담기 견적문의 |
|
| AS-62455 | Biotin-LC-beta-Amyloid (22-41), Human, mouse/rat | 1 mg | Anaspec | This is amino acids 22 to 41 fragment of beta-amyloid peptide, biotinylated through an LC spacer at the N-terminus. | |
카트담기 견적문의 |
|
| AS-62465 | Beta-Amyloid (1-28)-Lys(Biotin)-NH2, Human | 0.5 mg | Anaspec | This is amino acids 1 to 28 fragment of the b-amyloid peptide biotinylated on the side chain of lysine. | |
카트담기 견적문의 |
|
| AS-62473 | Beta-Amyloid (1-17)-Cys, Human | 1 mg | Anaspec | This peptide amino acids 1 to 17 is a modified fragment of the b-amyloid peptide, with cysteine substituted for valine at position 17. | |
카트담기 견적문의 |
|
| AS-62476 | Beta-Amyloid (1-38), mouse, rat | 1 mg | Anaspec | Beta-Amyloid Peptides - Mouse/Rat | |
카트담기 견적문의 |
|
| AS-62478 | [Met(O)35]-beta-Amyloid (1-42), Human | 0.5 mg | Anaspec | Beta-Amyloid (1-42) and Related Peptides | |
카트담기 견적문의 |
|
| AS-62762 | Amyloid-Forming Peptide GNNQQNY | 1 mg | Anaspec | This is a heptapeptide from the N-terminal prion-determining domain of the yeast protein Sup35 that forms amyloid fibrils. The availability of its detailed atomic oligomeric structure makes it a good model for studying the early stage of aggregation. The GNNQQNY dimer forms three stable sheet structures. in-register parallel, off-register parallel, and anti-parallel. The in-register parallel dimer, which is close to the amyloid beta-sheet structure, has few interpeptide hydrogen bonds, making hydrophobic interactions more important and increasing the conformational entropy compared to the anti-parallel sheet. | |
카트담기 견적문의 |
|
| AS-62766 | Beta-Amyloid (23-42), Human, mouse/rat | 1 mg | Anaspec | This is amino acids 23 to 42 fragment of beta-amyloid. | |
카트담기 견적문의 |
|
| AS-62884 | Beta-Amyloid (11-25), Human | 1 mg | Anaspec | This amino acids 11 to 22 fragment of b-amyloid is capable of forming well-organized amyloid fibrils in vitro, similar to the pathogenic ones found in amyloidosis. Analysis of the structural properties of one monomer of b-amyloid (11-22) as well as of the aggregation mechanisms for four chains of b-amyloid (11-22) showed that the system assembles rapidly into a random globular state that evolves into three- and four-stranded antiparallel beta-sheets. The aggregation process is considerably accelerated by the presence of preformed dimers. | |
카트담기 견적문의 |
|
| AS-62885 | Beta-Amyloid (10-26), Human | 1 mg | Anaspec | This is amino acids 10 to 26 fragment of beta-Amyloid peptide. It is capable of forming fibrils. | |
카트담기 견적문의 |
|
| AS-62897 | Beta-Amyloid (16-22), Human, mouse/rat | 1 mg | Anaspec | This is a short fragment of the b-Amyloid peptide containing two aromatic phenylalanine residues. Short peptide models have provided novel insight into the mechanistic issues of amyloid formation. This heptapeptide fragment has the capacity of forming typical amyloid fibrils in vitro. Aromatic interactions are important in many cases of amyloid formation. | |
카트담기 견적문의 |
|
| AS-62907 | Biotin-LC-beta-Amyloid (15-25), Human, mouse/rat | 1 mg | Anaspec | Beta-Amyloid Peptide Fragments | |
카트담기 견적문의 |
|
| AS-62950 | Beta-Amyloid (11-40), FAM-labeled, Human | 0.1 mg | Anaspec | Beta-Amyloid (1-40) and Related Peptides | |
카트담기 견적문의 |
|
| AS-62966 | Beta-Amyloid (1-22), Human | 1 mg | Anaspec | This is amino acids 1 to 22 fragment of the beta-amyloid peptide | |
카트담기 견적문의 |
|
| AS-62967 | Beta-Amyloid (1-12), Human | 1 mg | Anaspec | This is amino acids 1 to 12 fragment of the beta-amyloid peptide. This N-terminal sequence was used to develop the antibody BR88. An antiserum directed against this peptide stained numerous tangle-bearing cells and bodies, as well as the neuritic component of plaques and neuropil threads. It stained a large number of pyramid cells. | |
카트담기 견적문의 |
|
| AS-63308 | Beta-Amyloid (25-35), HiLyte™ Fluor 488-labeled, Human, mouse/rat | 0.1 mg | Anaspec | This is amino acids 25 to 35 fragment of beta-amyloid peptide labeled with HiLyte™ Fluor 488, Abs/Em=503/528 nm. | |
카트담기 견적문의 |
|
| AS-63317 | Beta-Amyloid (11-42), Human | 1 mg | Anaspec | This is amino acids 11 to 42 fragment of beta-amyloid. This peptide was detected in Alzheimer disease brains within several principal beta-amyloid variants. | |
카트담기 견적문의 |
|
| AS-63320 | [Asn7]-beta-Amyloid (1-40), Tottori-Japanese Mutation, Human | 0.5 mg | Anaspec | Beta-Amyloid (1-40) and Related Peptides | |
카트담기 견적문의 |
|
| AS-63321 | [Arg6]-beta-Amyloid (1-40), English Mutation, Human | 0.5 mg | Anaspec | Beta-Amyloid (1-40) and Related Peptides | |
카트담기 견적문의 |
|
| AS-63323 | [Arg6]-beta-Amyloid (1-42), English Mutation, Human | 0.5 mg | Anaspec | This is amino acids 1 to 42 beta-amyloid with the England mutation where His6 is replaced by Arg6. This novel familial Alzheimer’s disease (FAD) -linked APP mutation accelerates the fibril elongation rate without a concomitant increase in the levels of protofibrils. The proband in the English family was diagnosed at 55 years of age. | |
카트담기 견적문의 |
|
| AS-63324 | [Asn7]-beta-Amyloid (1-42), Tottori-Japanese Mutation, Human | 0.5 mg | Anaspec | This b-amyloid (1-42) contains the Tottori-Japanese (D7N) mutation where Asp7 is replaced by Asn7. In vitro analysis using beta-amyloid 1 to 40-based mutant peptide reveals that the D7N mutation does not accelerate the nucleation phase but selectively promotes the elongation phase of amyloid fibril formation. The levels of protofibrils generated from D7N beta-amyloid were markedly inhibited despite enhanced fibril formation. | |
카트담기 견적문의 |
|
| AS-63327 | Beta-Amyloid (11-42), HiLyte™ Fluor 488-labeled, Human | 0.1 mg | Anaspec | This is amino acids 11 to 42 fragment of b-amyloid peptide labeled with HiLyte™ Fluor 488, Abs/Em=503/528 nm. Post-mortem Alzheimer’s diseased (AD) brain specimens reveal significant levels of this b -amyloid peptide within the insoluble amyloid pools. HiLyte™ Fluor 488-labeled b-amyloid (11-42) has a brighter intensity than FITC or FAM-labeled b-amyloid (11-42). | |
카트담기 견적문의 |
|
| AS-63335 | Beta-Amyloid (1-55), Human | 0.1 mg | Anaspec | Beta-Amyloid (1-43) to (1-49) and (1-55) Peptides | |
카트담기 견적문의 |
|
| AS-63356 | Beta-Amyloid (1-40)-Lys(Biotin)-NH2, mouse, rat | 0.1 mg | Anaspec | Beta-Amyloid Peptides - Mouse/Rat | |
카트담기 견적문의 |
|
| AS-63671-1 | [Cys26]-beta-Amyloid (1-40), S26C beta-Amyloid (1-40), Human | 1 mg | Anaspec | Beta-Amyloid (1-40) and Related Peptides | |
카트담기 견적문의 |
|
| AS-63672-05 | [Cys26]-beta-Amyloid (1-42), S26C beta-Amyloid (1-42), Human | 0.5 mg | Anaspec | Beta-Amyloid (1-42) and Related Peptides | |
카트담기 견적문의 |
|
| AS-63672-1 | [Cys26]-beta-Amyloid (1-42), S26C beta-Amyloid (1-42), Human | 1 mg | Anaspec | Beta-Amyloid (1-42) and Related Peptides | |
카트담기 견적문의 |
|
| AS-63704 | [Gly21]-beta-Amyloid (1-42), A21G Flemish Mutation, Human | 0.5 mg | Anaspec | Beta-Amyloid (1-42) and Related Peptides | |
카트담기 견적문의 |
|
| AS-63705 | [Asn23]-beta-amyloid (1-42), Iowa Mutation, Human | 0.5 mg | Anaspec | Beta-Amyloid (1-42) and Related Peptides | |
카트담기 견적문의 |
|
| AS-63715-01 | Beta-Amyloid (3-42), Human | 0.1 mg | Anaspec | Beta-Amyloid (1-42) and Related Peptides | |
카트담기 견적문의 |
|
| AS-63715-1 | Beta-Amyloid (3-42), Human | 1 mg | Anaspec | Beta-Amyloid (1-42) and Related Peptides | |
카트담기 견적문의 |
|
| AS-63737 | ClearPoint™ beta-Amyloid (1-40), 13C, 15N-labeled at Arg & Lys, Human | 50 µg | Anaspec | ClearPoint™ beta-Amyloid (1-40) is a heavy-isotope labeled peptide. All the Arginine and Lysines have universally labeled 13C and 15N. | |
카트담기 견적문의 |
|
| AS-63738 | ClearPoint™ beta-Amyloid (1-42), 13C, 15N-labeled at Arg & Lys, Human | 50 µg | Anaspec | ClearPoint™ beta-Amyloid (1-42) is a heavy-isotope labeled peptide. All the Arginine and Lysines have universally labeled 13C and 15N. | |
카트담기 견적문의 |
|
| AS-63745 | Beta-Amyloid (10-35)-Lys(Biotin)-NH2, Human | 0.1 mg | Anaspec | This is beta-amyloid (10-35) with a Lys added on the C-terminus, biotin is attached to the side chain of this Lys. | |
카트담기 견적문의 |
|
| AS-63819 | Beta-Amyloid (11-17), Human | 1 mg | Anaspec | This is a short fragment of the b-Amyloid peptide containing Histidine 13 and 14. Alzheimer’s beta amyloid peptides form A?Ion Channels in lipid bilayers. It is postulated thatIon Channel activity of A? is related to cytotoxic activity of A?. Small peptides that contain the amino acid sequence of the predicted mouth region of the A? channel pore can inhibit A?Ion Channel activity. And, Histidines 13 and 14 have been shown to be essential for the peptide to inhibit Alzheimer’s disease A?Ion Channel and cytotoxicity. | |
카트담기 견적문의 |
|
| AS-64128-05 | Beta-Amyloid (1-40) • HFIP, Human | 0.5 mg | Anaspec | Removal of any preexisting structures in lyophilized stocks of Aβ-peptide is the critical initial step for controlled aggregation studies. HFIP has been shown to break down β-sheet structure, disrupt hydrophobic forces in aggregated amyloid preparations, and promotes α-helical secondary structure. HFIP treatment of lyophilized Aβ-peptide resulted in a dense, homogeneous preparation of unaggregated peptide and samples can be stored as peptide films. | |
카트담기 견적문의 |
|
| AS-64128-1 | Beta-Amyloid (1-40) • HFIP, Human | 1 mg | Anaspec | Removal of any pre-existing structures in lyophilized stocks of Aβ-peptide is the critical initial step for controlled aggregation studies. HFIP has been shown to break down β-sheet structure, disrupt hydrophobic forces in aggregated amyloid preparations, and promotes α-helical secondary structure. HFIP treatment of lyophilized Aβ-peptide resulted in a dense, homogeneous preparation of unaggregated peptide and samples can be stored as peptide films. | |
카트담기 견적문의 |
|
| AS-64129-05 | Beta-Amyloid (1-42) • HFIP, Human | 0.5 mg | Anaspec | Removal of any preexisting structures in lyophilized stocks of Aβ-peptide is the critical initial step for controlled aggregation studies. HFIP has been shown to break down β-sheet structure, disrupt hydrophobic forces in aggregated amyloid preparations, and promotes α-helical secondary structure. HFIP treatment of lyophilized Aβ-peptide resulted in a dense, homogeneous preparation of unaggregated peptide and samples can be stored as peptide films. | |
카트담기 견적문의 |
|
| AS-64129-1 | Beta-Amyloid (1-42) • HFIP, Human | 1 mg | Anaspec | Removal of any preexisting structures in lyophilized stocks of Aβ-peptide is the critical initial step for controlled aggregation studies. HFIP has been shown to break down β-sheet structure, disrupt hydrophobic forces in aggregated amyloid preparations, and promotes α-helical secondary structure. HFIP treatment of lyophilized Aβ-peptide resulted in a dense, homogeneous preparation of unaggregated peptide and samples can be stored as peptide films. | |
카트담기 견적문의 |
|
| AS-64161 | Beta-Amyloid (1-42), HiLyte™ Fluor 647-labeled, Human | 0.1 mg | Anaspec | This beta-amyloid (1-42) peptide is labeled on the N-terminus with HiLyte™ Fluor 647, Abs/Em = 649/674 nm. | |
카트담기 견적문의 |
|
| AS-64478 | Beta-Amyloid (1-10), Human | 1 mg | Anaspec | This peptide is beta-Amyloid (1-10), human sequence. | |
카트담기 견적문의 |
|
| AS-64480 | Beta-Amyloid (1-13), Human | 1 mg | Anaspec | This peptide is beta-Amyloid (1-13), human sequence. | |
카트담기 견적문의 |
|
| AS-64519 | [Met]-beta-Amyloid (1-42), 5-TAMRA labeled, Human | 0.1 mg | Anaspec | This is b-amyloid (1-42) peptide with an N-terminal methionine is labeled with a fluorescent dye, 5-TAMRA (Ex/Em= 544/572 nm), on the N-terminus. | |
카트담기 견적문의 |
|
| AS-64793 | Beta-Amyloid (3-16), Human | 1 mg | Anaspec | This peptide is amino acids 3 to 16 fragment of beta-Amyloid (Aß) with an N-terminal deletion that alters the coordination environment for the Cu2+ binding site. Oxidation targets for Aß (1-16) are the histidine residues coordinated to the meta | |
카트담기 견적문의 |
|
| AS-65113 | [Pro18]-Beta-Amyloid (12-28); V8P Beta-Amyloid (12-28); Aβ12-28P, Human | 1 mg | Anaspec | This peptide is derived from Aβ (12-28), which represents a binding site for apolipoprotein E (apoE). apoE is a genetically inherited risk factor for Alzheimer’s disease that promotes aggregation of toxic Aβ. Substitution of Val18 to proline competitively | |
카트담기 견적문의 |
|
| AS-65178 | [Pro19]-beta-Amyloid (1-42); F19P beta-Amyloid (1-42), Human | 1 mg | Anaspec | This peptide is beta-amyloid (1-42) with substitution of Phe19 to Pro. This substitution inhibits amyloid fibril formation, which is implicated in neurodegenerative diseases such as Alzheimer’s. | |
카트담기 견적문의 |
|
| AS-65220 | ClearPoint™ beta-Amyloid (1-38), 13C-Phe & Ile, Human | 0.05 mg | Anaspec | This peptide is beta-amyloid (1-38) with phenylalanine and isoleucine universally labeled with 13C. Ab is found in amyloid deposits of Alzheimer’s patients and is implicated in the pathogenesis of this disease. | |
카트담기 견적문의 |
|
| AS-65579 | Amyloid Bri (1-23) | 1 mg | Anaspec | Amyloid Bri(1-23) and Amyloid Bri(1-34) peptides are post-translational products of mutated BRI2 gene. Amyloid Bri peptides are found as plaques in brains of patients with Familiar British Dementia (FBD) that shares many common features with Alzheimer’s Disease. | |
카트담기 견적문의 |
|
| AS-65580 | Amyloid Bri (1-34) | 1 mg | Anaspec | Amyloid Bri (1-23) and Amyloid Bri (1-34) peptides are post-translational products of the mutated BRI2 gene. Amyloid Bri peptides are found as plaques in the brains of patients with Familiar British Dementia (FBD), a condition that shares common features with Alzheimer’s Disease. | |
카트담기 견적문의 |
|
| AS-72215 | AggreSure™ β-Amyloid (1-40), human | 0.25 mg | Anaspec | Beta-Amyloid (1-40) and Related Peptides | |
카트담기 견적문의 |
|
| AS-72216 | AggreSure™ β-Amyloid (1-42), Human | 0.25 mg | Anaspec | Beta-Amyloid (1-42) and Related Peptides | |
카트담기 견적문의 |
| 전체선택 | |
|---|---|
|
Beta-Amyloid (1-42), Human
|
|
|
Beta-Amyloid (1-15)-Lys16(HiLyte™ Fluor 488), Human
|
|
|
SensoLyte® Fluorescent ß-Amyloid (1-42) Sampler Kit, Human
|
|
|
GMP beta-Amyloid (1-42), human (Ammonium Salt)
|
|
|
GMP beta-Amyloid (1-42), human (Ammonium Salt)
|
|
|
GMP beta-Amyloid (1-40), human (Ammonium Salt)
|
|
|
GMP beta-Amyloid (1-40), human (Ammonium Salt)
|
|
|
Beta-Amyloid (1-42), Human
|
|
|
Beta-Amyloid (1-42), Human
|
|
|
Beta-Amyloid (1-42), Human
|
|
|
Beta-Amyloid (1-40) • HCl, Human
|
|
|
Beta-Amyloid (1-42) • HCl, Human
|
|
|
Beta-Amyloid (1-42) • HCl, Human
|
|
|
Beta-Amyloid (17-40), Human, mouse/rat
|
|
|
Beta-Amyloid (17-40), Human, mouse/rat
|
|
|
Beta-Amyloid (40-1), Human
|
|
|
Beta-Amyloid (40-1), Human
|
|
|
Beta-Amyloid (1-11), Human
|
|
|
Beta-Amyloid (22-35), Human, mouse/rat
|
|
|
Beta-Amyloid (1-40) • HCl, Human
|
|
|
Beta-Amyloid (25-35) • HCl, Human, mouse/rat
|
|
|
Biotin-beta-Amyloid (1-40), Human
|
|
|
Biotin-beta-Amyloid (1-40), Human
|
|
|
Beta-Amyloid (1-40), FAM-labeled, Human
|
|
|
Beta-Amyloid (1-40), FAM-labeled, Human
|
|
|
Beta-Amyloid (1-40)-Lys(Biotin-LC), Human
|
|
|
Beta-Amyloid (1-40)-Lys(Biotin-LC), Human
|
|
|
Cys-beta-Amyloid (1-40), Human
|
|
|
Biotin-beta-Amyloid (1-42), Human
|
|
|
Biotin-beta-Amyloid (1-42), Human
|
|
|
Beta-Amyloid (1-42), FAM-labeled, Human
|
|
|
Beta-Amyloid (1-42), FAM-labeled, Human
|
|
|
Cys-beta-Amyloid (1-42), Human
|
|
|
Cys-beta-Amyloid (1-42), Human
|
|
|
Biotin-beta-Amyloid (17-40), Human, mouse/rat
|
|
|
Beta-Amyloid (11-22), Human
|
|
|
Beta-Amyloid (1-16), Human
|
|
|
Beta-Amyloid (1-16), Human
|
|
|
Beta-Amyloid (25-35), Human, mouse/rat
|
|
|
Beta-Amyloid (25-35), Human, mouse/rat
|
|
|
Beta-Amyloid (12-28), Human
|
|
|
Beta-Amyloid (12-28), Human
|
|
|
Beta-Amyloid (1-28), Human
|
|
|
Beta-Amyloid (1-28), Human
|
|
|
Beta-Amyloid (1-28), Human
|
|
|
Beta-Amyloid (1-38), Human
|
|
|
Beta-Amyloid (1-38), Human
|
|
|
Beta-Amyloid (1-40), Human
|
|
|
Beta-Amyloid (1-40), Human
|
|
|
Beta-Amyloid (1-40), Human
|
|
|
Beta-Amyloid (1-39), Human
|
|
|
Beta-Amyloid (1-39), Human
|
|
|
Scrambled-beta-Amyloid (1-40), Human
|
|
|
Scrambled-beta-Amyloid (1-40), Human
|
|
|
Biotin-LC-beta-Amyloid (1-42), Human
|
|
|
Biotin-LC-beta-Amyloid (1-42), Human
|
|
|
Biotin-LC-beta-Amyloid (1-40), Human
|
|
|
Biotin-LC-beta-Amyloid (1-40), Human
|
|
|
Biotin-LC-beta-Amyloid (1-40), Human
|
|
|
Beta-Amyloid Peptide (1-40), mouse, rat
|
|
|
Beta-Amyloid Peptide (1-42), mouse, rat
|
|
|
Beta-Amyloid (1-43), Human
|
|
|
Beta-Amyloid (1-43), Human
|
|
|
Beta-Amyloid (10-20), Human
|
|
|
Beta-Amyloid Peptide (1-40), mouse, rat
|
|
|
Beta-Amyloid Peptide (1-42), mouse, rat
|
|
|
Scrambled-beta-Amyloid (1-42), Human
|
|
|
Scrambled-beta-Amyloid (1-42), Human
|
|
|
Beta-Amyloid (42-1), Human
|
|
|
Beta-Amyloid (42-1), Human
|
|
|
Beta-Amyloid (42-1), Human
|
|
|
[Pyr11]-beta-Amyloid (11-42), Human
|
|
|
[Pyr11]-beta-Amyloid (11-42), Human
|
|
|
[Pyr11]-beta-Amyloid (11-40), Human
|
|
|
Beta-Amyloid (2-40), Human
|
|
|
[Pyr3]-beta-Amyloid (3-40), Human
|
|
|
[Pyr3]-beta-Amyloid (3-40), Human
|
|
|
[Pyr3]-beta-Amyloid (3-42), Human
|
|
|
[Pyr3]-beta-Amyloid (3-42), Human
|
|
|
Beta-Amyloid (4-42), Human
|
|
|
Beta-Amyloid (2-42), Human
|
|
|
Beta-Amyloid (2-42), Human
|
|
|
Beta-Amyloid (11-40), Human
|
|
|
Beta-Amyloid (9-42), Human
|
|
|
Beta-Amyloid (5-42), Human
|
|
|
Beta-Amyloid (5-42), Human
|
|
|
Beta-Amyloid (1-33), Human
|
|
|
Beta-Amyloid (1-37), Human
|
|
|
Beta-Amyloid (1-37), Human
|
|
|
Beta-Amyloid (1-36), Human
|
|
|
Beta-Amyloid (1-42), TAMRA-labeled, Human
|
|
|
Beta-Amyloid (1-42), HiLyte™ Fluor 488-labeled, Human
|
|
|
Beta-Amyloid (1-42), HiLyte™ Fluor 555-labeled, Human
|
|
|
Beta-Amyloid (1-40), TAMRA-labeled, Human
|
|
|
Beta-Amyloid (1-40), HiLyte™ Fluor 488-labeled, Human
|
|
|
Beta-Amyloid (1-40), HiLyte™ Fluor 555-labeled, Human
|
|
|
Beta-Amyloid (1-40), HiLyte™ Fluor 647-labeled, Human
|
|
|
Beta-Amyloid (1-42), sodium salt, Human
|
|
|
Beta-Amyloid (1-42), sodium salt, Human
|
|
|
Beta-Amyloid (1-42), Scrambled, 5-FAM labeled, Human
|
|
|
Beta-Amyloid (3-40), Human
|
|
|
[Gln22]-beta-Amyloid (1-40), Dutch Mutation, Human
|
|
|
[Gly22]-beta-Amyloid (1-40), Arctic Mutation, Human
|
|
|
Beta-Amyloid (1-40)-Lys(Biotin)-NH2, Human
|
|
|
Beta-Amyloid (1-40)-Lys(Biotin)-NH2, Human
|
|
|
Beta-Amyloid (1-42)-Lys(Biotin)-NH2, Human
|
|
|
Beta-Amyloid (1-42)-Lys(Biotin)-NH2, Human
|
|
|
Beta-Amyloid (1-15), Human
|
|
|
Beta-Amyloid (1-34), Human
|
|
|
Beta-Amyloid (13-28), Human
|
|
|
[NMeG24, NMeI26] Human Islet Amyloid Polypeptide (IAPP) (22 - 27)
|
|
|
Beta-Amyloid (1-17), Human
|
|
|
Beta-Amyloid (1-40)-Lys(LC-biotin)-NH2, FAM-labeled, Human
|
|
|
[Gly22]-beta-Amyloid (1-42), E22G Arctic Mutation, Human
|
|
|
Beta-Amyloid (1-9), Human
|
|
|
Beta-Amyloid (25-35), scrambled, Human, mouse/rat
|
|
|
Beta-Amyloid (22-42), Human, mouse/rat
|
|
|
Beta-Amyloid (17-24), Human, mouse/rat
|
|
|
Beta-Amyloid (20-42), Human, mouse/rat
|
|
|
Beta-Amyloid A4 Protein Precursor (740-770), APP (C31)
|
|
|
Beta-Amyloid (1-16)-Lys(Biotin-LC)-NH2, Human
|
|
|
[Gln22]-beta-Amyloid (1-42), E22Q Dutch Mutation, Human
|
|
|
[Asn23]-beta-Amyloid (1-40), Iowa Mutation, Human
|
|
|
[Gln22, Asn23]-beta-Amyloid (1-40), E22Q/D23N Dutch/Iowa double mutation, Human
|
|
|
[Lys22]-beta-Amyloid (1-40), Italian Mutation, Human
|
|
|
[Lys22]-beta-Amyloid (1-42), Italian Mutation, Human
|
|
|
[Gly21]-beta-Amyloid (1-40), A21G, Flemish Mutation, Human
|
|
|
Beta-Amyloid (1-40)-Cys, Human
|
|
|
Beta-Amyloid (1-40) Binding Peptide, Biotin-labeled
|
|
|
Beta-Amyloid (17-28), Human, mouse/rat
|
|
|
Biotin-beta-Amyloid (25-35), Human, mouse/rat
|
|
|
Biotin-LC-beta-Amyloid (22-41), Human, mouse/rat
|
|
|
Beta-Amyloid (1-28)-Lys(Biotin)-NH2, Human
|
|
|
Beta-Amyloid (1-17)-Cys, Human
|
|
|
Beta-Amyloid (1-38), mouse, rat
|
|
|
[Met(O)35]-beta-Amyloid (1-42), Human
|
|
|
Amyloid-Forming Peptide GNNQQNY
|
|
|
Beta-Amyloid (23-42), Human, mouse/rat
|
|
|
Beta-Amyloid (11-25), Human
|
|
|
Beta-Amyloid (10-26), Human
|
|
|
Beta-Amyloid (16-22), Human, mouse/rat
|
|
|
Biotin-LC-beta-Amyloid (15-25), Human, mouse/rat
|
|
|
Beta-Amyloid (11-40), FAM-labeled, Human
|
|
|
Beta-Amyloid (1-22), Human
|
|
|
Beta-Amyloid (1-12), Human
|
|
|
Beta-Amyloid (25-35), HiLyte™ Fluor 488-labeled, Human, mouse/rat
|
|
|
Beta-Amyloid (11-42), Human
|
|
|
[Asn7]-beta-Amyloid (1-40), Tottori-Japanese Mutation, Human
|
|
|
[Arg6]-beta-Amyloid (1-40), English Mutation, Human
|
|
|
[Arg6]-beta-Amyloid (1-42), English Mutation, Human
|
|
|
[Asn7]-beta-Amyloid (1-42), Tottori-Japanese Mutation, Human
|
|
|
Beta-Amyloid (11-42), HiLyte™ Fluor 488-labeled, Human
|
|
|
Beta-Amyloid (1-55), Human
|
|
|
Beta-Amyloid (1-40)-Lys(Biotin)-NH2, mouse, rat
|
|
|
[Cys26]-beta-Amyloid (1-40), S26C beta-Amyloid (1-40), Human
|
|
|
[Cys26]-beta-Amyloid (1-42), S26C beta-Amyloid (1-42), Human
|
|
|
[Cys26]-beta-Amyloid (1-42), S26C beta-Amyloid (1-42), Human
|
|
|
[Gly21]-beta-Amyloid (1-42), A21G Flemish Mutation, Human
|
|
|
[Asn23]-beta-amyloid (1-42), Iowa Mutation, Human
|
|
|
Beta-Amyloid (3-42), Human
|
|
|
Beta-Amyloid (3-42), Human
|
|
|
ClearPoint™ beta-Amyloid (1-40), 13C, 15N-labeled at Arg & Lys, Human
|
|
|
ClearPoint™ beta-Amyloid (1-42), 13C, 15N-labeled at Arg & Lys, Human
|
|
|
Beta-Amyloid (10-35)-Lys(Biotin)-NH2, Human
|
|
|
Beta-Amyloid (11-17), Human
|
|
|
Beta-Amyloid (1-40) • HFIP, Human
|
|
|
Beta-Amyloid (1-40) • HFIP, Human
|
|
|
Beta-Amyloid (1-42) • HFIP, Human
|
|
|
Beta-Amyloid (1-42) • HFIP, Human
|
|
|
Beta-Amyloid (1-42), HiLyte™ Fluor 647-labeled, Human
|
|
|
Beta-Amyloid (1-10), Human
|
|
|
Beta-Amyloid (1-13), Human
|
|
|
[Met]-beta-Amyloid (1-42), 5-TAMRA labeled, Human
|
|
|
Beta-Amyloid (3-16), Human
|
|
|
[Pro18]-Beta-Amyloid (12-28); V8P Beta-Amyloid (12-28); Aβ12-28P, Human
|
|
|
[Pro19]-beta-Amyloid (1-42); F19P beta-Amyloid (1-42), Human
|
|
|
ClearPoint™ beta-Amyloid (1-38), 13C-Phe & Ile, Human
|
|
|
Amyloid Bri (1-23)
|
|
|
Amyloid Bri (1-34)
|
|
|
AggreSure™ β-Amyloid (1-40), human
|
|
|
AggreSure™ β-Amyloid (1-42), Human
|
관련제품
| Cat No. | 품명 | 규격 | 제조사 | 제품정보 | 수량 | 견적문의 | |
|---|---|---|---|---|---|---|---|
| AS-55921 | Anti-β-Amyloid (1-40), mouse monoclonal | 50 µg | Anaspec | Clone: MM32-13.1.1, Isotype: IgG1, Amount: 50 µg in 250 µl at 0.2 mg/ml concentration. Product Description: This mouse monoclonal antibody is supplied as a purified IgG1 in 250 µl of 40 mM MOPS buffer (pH 7.5) containing 0.1% BSA, 50% glycerol, 0.1% sodium azide. Immunogen: Synthetic peptide corresponding to aa 35-40 of β-amyloid (1-40). Species Reactivity: This antibody will recognize human, mouse, and rat β-amyloid (1-40). Specificity was confirmed using sandwich ELISA and Immunohistochemistry.This antibody does not cross-react with β-amyloid (1-37), β-amyloid (1-38), and β-amyloid (1-42) in sandwich ELISA when used at concentrations up to 50 ng/ml. Application Notes: The following concentration ranges are recommended starting points for this product. Optimal working concentrations for specific applications should be determined by the investigator. Immunohistochemistry: 0.5-1 µg/ml, Western Immunoblot: 0.5-1 µg/ml | |
카트담기 견적문의 |
|
| AS-55922 | Anti-β-Amyloid (1-42), mouse monoclonal | 50 µg | Anaspec | Clone: MM26-2.1.3, Isotype: IgG1, Amount: 50 µg in 250 µl at 0.2 mg/ml concentration. Product Description: This mouse monoclonal antibody is supplied as a purified IgG1 in 250 µl of 40 mM MOPS buffer (pH 7.5) containing 0.1% BSA, 50% glycerol, 0.1% sodium azide. Immunogen: Synthetic peptide corresponding to aa 35-42 of β-amyloid (1-42). Species Reactivity: This antibody will recognize human, mouse, and rat β-amyloid (1-42). Specificity was confirmed using sandwich ELISA and Immunohistochemistry.This antibody does not cross-react with β-amyloid (1-37), β-amyloid (1-38), and β-amyloid (1-40) in sandwich ELISA when used at concentrations up to 50 ng/ml. Application Notes: The following concentration ranges are recommended starting points for this product. Optimal working concentrations for specific applications should be determined by the investigator. Immunohistochemistry: 0.05-0.2 µg/ml, Western blot: 0.5-1 µg/ml | |
카트담기 견적문의 |
|
| AS-56074 | Anti-Human β-Amyloid (1-6) Antibody, Rabbit Polyclonal | 50 µg | Anaspec | Rabbit polyclonal antibody was raised against a synthetic peptide derived from first six amino acids of N-terminus of human β-amyloid. | |
카트담기 견적문의 |
|
| AS-56075 | Anti-Human β-Amyloid (17-23) Antibody, Rabbit Polyclonal | 50 µg | Anaspec | Rabbit polyclonal antibody was raised against a synthetic peptide corresponding to 17-23 amino acids of human β-amyloid. | |
카트담기 견적문의 |
|
| AS-56076 | Anti-Human β-Amyloid (23-29) Antibody, Rabbit Polyclonal | 50 µg | Anaspec | Rabbit polyclonal antibody was raised against a synthetic peptide corresponding to 23-29 amino acids of human β-amyloid. | |
카트담기 견적문의 |
|
| AS-55553 | SensoLyte® Anti-Mouse/ Rat β-Amyloid (1-40) Quantitative ELISA *Colorimetric* | 1 kit | Anaspec | This SensoLyte® high-sensitivity (2pg/ml) beta-Amyloid (1-40) Quantitative ELISA Kit (Mouse/Rat) provides a convenient and quantitative assay for determining mouse/rat beta-Amyloid (1-40) (Aβ40) amount in cell and tissue lysate as well as in body fluids. Compared to other mouse/rat anti-Aβ40 ELISA kits on the market, it takes less time to run this assay. HRP conjugated detection antibody in this kit is added simultaneously with the samples and standards during the assay. This eliminates extra incubation and washing steps and makes this kit a one-step procedure for Aβ40 quantification. Alzheimer's Disease (AD) is the most common neurodegenerative disorder in elderly people. It has been demonstrated that AD has biological causes and is characterized by the presence of senile plaques and neurofibrillary tangles mainly in cerebral cortex and hippocampus brain regions.1-5 Beta-Amyloid (1-40) (Aβ40) and beta-Amyloid (1-42) (Aβ42) are the main components of the above plaques; however, other forms of beta-Amyloid peptides are also present. Both peptides are cleaved from the Amyloid Precursor Protein (APP) by β-secretase and γ-secretaseEnzymes.2,3,5 Many studies suggest that Aβ42 or/and Aβ43 are required to initiate formation of amyloid plaques and neurofibrills that leads to the neurodegeneration,1-5 while Aβ40 is less neurotoxic. | |
카트담기 견적문의 |
|
| AS-55554 | SensoLyte® Anti-Mouse/ Rat β-Amyloid (1-42) Quantitative ELISA *Colorimetric* | 1 kit | Anaspec | This SensoLyte® high-sensitivity (2pg/ml) beta-Amyloid (1-42) Quantitative ELISA Kit (Mouse/Rat) provides a convenient and quantitative assay for determining mouse/rat beta-Amyloid (1-42) (Aβ42) amount in cell and tissue lysate as well as in body fluids. Compared to other mouse/rat anti-Aβ42 ELISA kits on the market, it takes less time to run this assay. HRP conjugated detection antibody in this kit is added simultaneously with the samples and standards during the assay. This eliminates extra incubation and washing steps and makes this kit a one-step procedure for Aβ42 quantification. Alzheimer's Disease (AD) is the most common neurodegenerative disorder in elderly people. It has been demonstrated that AD has biological causes and is characterized by the presence of senile plaques and neurofibrillary tangles mainly in cerebral cortex and hippocampus brain regions.1-5 Beta-Amyloid (1-40) (Aβ40) and beta-Amyloid (1-42) (Aβ42) are the main components of the above plaques; however, other forms of beta-Amyloid peptides are also present. Both peptides are cleaved from the Amyloid Precursor Protein (APP) by β-secretase and γ-secretaseEnzymes.2,3,5 Many studies suggest that Aβ42 or/and Aβ43 are required to initiate formation of amyloid plaques and neurofibrills that leads to the neurodegeneration,1-5 while Aβ40 is less neurotoxic. | |
카트담기 견적문의 |
|
| AS-72213 | SensoLyte® Thioflavin T β-Amyloid (1-40) Aggregation Kit | 1 kit | Anaspec | The SensoLyte® ThT β-Amyloid (1-40) Aggregation kit provides a convenient and standard method to measure Aβ40 aggregation using Thioflavin T dye. Aβ40 peptide is pretreated to ensure it is in a monomeric state. An optimized fibrillation buffer is included with the kit, and two known inhibitors are supplied as controls. The assay is based on the property of ThT dye in which fluorescence (Ex/Em=440/484 nm) is increased when bound to aggregated Aβ peptides. Alzheimer's disease (AD), the most common cause of dementia, is characterized by the presence of senile plaques and neurofibrillary tangles, surrounded by damaged neurons. Beta-Amyloid (Aβ) peptides, Aβ40 (1-40) and Aβ42 (1-42), were found to be a major component of the above plaques. Many studies suggest that these peptides can form toxic oligomers and fibrils under physiological conditions and rapidly aggregate. Since Aβ aggregation is evidently an essential event in the pathogenesis of AD, a reliable assay is important to study Aβ fibrillation kinetics and screen for Aβ aggregation inhibitors. | |
카트담기 견적문의 |
|
| AS-72214 | SensoLyte® Thioflavin T β-Amyloid (1-42) Aggregation Kit | 1 kit | Anaspec | The SensoLyte® ThT β-Amyloid (1-42) Aggregation kit provides a convenient and standard method to measure Aβ42 aggregation using Thioflavin T dye. Aβ42 peptide is pretreated to ensure it is in a monomeric state. An optimized fibrillation buffer is included with the kit, and two known inhibitors are supplied as controls. The assay is based on the property of ThT dye in which fluorescence (Ex/Em=440/484 nm) is increased when bound to aggregated Aβ peptides. Alzheimer's disease (AD), the most common cause of dementia, is characterized by the presence of senile plaques and neurofibrillary tangles, surrounded by damaged neurons. Beta-Amyloid (Aβ) peptides, Aβ40 (1-40) and Aβ42 (1-42), were found to be a major component of the above plaques. Many studies suggest that these peptides can form toxic oligomers and fibrils under physiological conditions and rapidly aggregate. Since Aβ aggregation is evidently an essential event in the pathogenesis of AD, a reliable assay is important to study Aβ fibrillation kinetics and screen for Aβ aggregation inhibitors. | |
카트담기 견적문의 |
| 전체선택 | |
|---|---|
|
Anti-β-Amyloid (1-40), mouse monoclonal
|
|
|
Anti-β-Amyloid (1-42), mouse monoclonal
|
|
|
Anti-Human β-Amyloid (1-6) Antibody, Rabbit Polyclonal
|
|
|
Anti-Human β-Amyloid (17-23) Antibody, Rabbit Polyclonal
|
|
|
Anti-Human β-Amyloid (23-29) Antibody, Rabbit Polyclonal
|
|
|
SensoLyte® Anti-Mouse/ Rat β-Amyloid (1-40) Quantitative ELISA *Colorimetric*
|
|
|
SensoLyte® Anti-Mouse/ Rat β-Amyloid (1-42) Quantitative ELISA *Colorimetric*
|
|
|
SensoLyte® Thioflavin T β-Amyloid (1-40) Aggregation Kit
|
|
|
SensoLyte® Thioflavin T β-Amyloid (1-42) Aggregation Kit
|
최근 본 제품
제품 문의 02-3471-6500 042-824-7000
AS 문의 02-3471-8171 온라인 접수 